Abstract library

3 results for "Christen".
#1084 Pancreatic Neuroendocrine Tumors in Denmark and Introduction of Cancer Package Pathways
Introduction: New referral procedures were introduced into the Danish healthcare system on Jan 1, 2009 in malignant diseases. Cancer-package pathways purposed to streamline diagnostics and treatment specifically to reduce the waiting time from diagnosis to initiation of specialized treatment.
Conference: 12th Annual ENETS Conference (2015)
Category: Epidemiology/Natural history/Prognosis - Descriptive epidemiology
Presenting Author: BA Claus Uhrenholt Christensen
#1172 Dual Inhibition of PI3K and mTORC1/C2 by PKI-587 (PF-05212384) as a Promising Therapeutic Option for Gastroenteropancreatic Neuroendocrine Tumor Disease and Its Effect on AKT-Signaling
Introduction: Gastroenteropancreatic neuroendocrine neoplasms (GEP-NEN) are heterogeneous in their clinical behavior and therapeutic options are still not satisfactory. The “crosstalk” of different signaling pathways in NEN cells appears to be more complex as known already. PKI-587 is a highly potent novel dual inhibitor of PI3K and mTORC1/C2.
Conference: 12th Annual ENETS Conference (2015)
Category: Basic Science - mTOR and other pathways, signalling, receptors
Presenting Author: Helma Freitag
#1404 The Proteasome Inhibitor Bortezomib Is a Highly Effective Treatment Option for Gastroenteropancreatic Neuroendocrine Neoplasms and Sensitizes to DNA Damaging Therapy In Vitro
Introduction: Gastroenteropancreatic neuroendocrine neoplasms are fairly rare tumors with very heterogeneous behavior and molecular characteristics. Their generally slow proliferation render them virtually resistant to many DNA damaging therapeutic approaches. Bortezomib has been shown to be effective in GEP-NENs in vitro but has been withdrawn from clinical assessment due to a small phase II study on bortezomib monotherapy in 2004.
Conference: 13th Annual ENETS conference (2016)
Category: Medical treatment - Targeted therapies
Presenting Author: Franziska Briest